Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gadobenate Dimeglumine→

Gadobenate Dimeglumine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
127000-20-8
Molecular formula
C36H62GdN5O21
Molecular weight
1058.1 g/mol
Drug class
Gadolinium-based paramagnetic magnetic-resonance imaging (MRI) contrast agent
Mechanism of action
A gadolinium chelate that develops a magnetic moment in a magnetic field and shortens the T1 and, to a lesser extent, T2 relaxation times of nearby water protons, increasing MRI signal intensity.
Indications / reported uses
  • Contrast enhancement in MRI of the central nervous system and selected liver imaging applications, according to the product label and jurisdiction.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gadobenate-dimeglumine · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f63abe56-46d9-4e32-afb1-f4e22370717d

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Gadolinium-based paramagnetic magnetic-resonance imaging (MRI) contrast agent

Mechanism of action

A gadolinium chelate that develops a magnetic moment in a magnetic field and shortens the T1 and, to a lesser extent, T2 relaxation times of nearby water protons, increasing MRI signal intensity.

General use cases

  • Contrast enhancement in MRI of the central nervous system and selected liver imaging applications, according to the product label and jurisdiction.
Active moiety: gadobenate chelate (gadolinium complex) (Related chemical form or complex; use the note below to understand the identity distinction.)

The active imaging entity is the intact gadolinium–gadobenate chelate, not free gadolinium or meglumine. This is a coordination complex/radiology contrast agent; do not merge with other gadolinium chelates.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Gadobenate Dimeglumine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gadobenate Dimeglumine Permitted Daily Exposure (PDE) report (the Gadobenate Dimeglumine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gadobenate Dimeglumine Occupational Exposure Limit (OEL) report (the Gadobenate Dimeglumine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.